Investigating the role of zinc protoporphyrin in brain damage after bleeding in the brain

Endogenous zinc protoporphyrin in intracerebral hemorrhage

NIH-funded research State University New York Stony Brook · NIH-11048804

This study is looking at how a substance called zinc protoporphyrin (ZnPP) affects brain damage after a type of bleeding in the brain, hoping to find new ways to help people recover better from this condition.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionState University New York Stony Brook NIH-funded
Lab location1 site (Stony Brook, United States)
Project IDNIH-11048804 on NIH RePORTER

What this research studies

This research focuses on understanding how zinc protoporphyrin (ZnPP), a compound formed in the brain after an intracerebral hemorrhage (ICH), contributes to brain damage. The study aims to identify the conditions that lead to the production of ZnPP and its mechanisms of neurotoxicity. By exploring the relationship between ICH, local tissue hypoxia, and ZnPP formation, the researchers hope to uncover new therapeutic targets that could mitigate brain injury. Patients may benefit from insights that could lead to improved treatments for ICH-related brain damage.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals who have experienced an intracerebral hemorrhage and are at risk of subsequent brain damage.

Not a fit: Patients who have not experienced an intracerebral hemorrhage or those with other unrelated neurological conditions may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies that significantly reduce brain damage and improve recovery outcomes for patients who suffer from intracerebral hemorrhage.

How similar studies have performed: While the specific approach of targeting ZnPP in ICH is novel, similar research has shown that addressing biochemical pathways involved in brain injury can lead to meaningful advancements in treatment.

Where this research is happening

Stony Brook, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acquired brain injuryAnti-Cancer Agentsanti-cancer drug
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.